Document Preview Unavailable
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
Menzel, Michael; Kirchner, Martina; Kluck, Klaus; Ball, Markus; Beck, Susanne; et al. The Journal of Pathology: Clinical Research Vol. 10, Iss. 2, (Mar 1, 2024).You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library




